Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals after mRNA vaccination

Cited by (641)

Items 101–200 of 641

1. Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose
   Laurent Rénia, Yun Shan Goh, Angéline Rouers, Nina Le Bert, Wan Ni Chia, Jean‐Marc Chavatte, Siew‐Wai Fong, Zi Wei Chang, Nicole Ziyi Zhuo, Matthew Zirui Tay et al. · 2022 · Nature Communications
2. Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses
   Wanting He, Rami Ghassan Musharrafieh, Ge Song, Katharina Dueker, Longping V. Tse, David R. Martinez, Alexandra Schäfer, Sean Callaghan, Peter Yong, Nathan Beutler et al. · 2022 · Nature Immunology
3. Guardians of the oral and nasopharyngeal galaxy: IgA and protection against SARS‐CoV ‐2 infection*
   Salma Sheikh‐Mohamed, Erin C. Sanders, Jennifer L. Gommerman, Michal Caspi Tal · 2022 · Immunological Reviews
4. COVID-19 Vaccination in Pregnancy and Lactation: Current Research and Gaps in Understanding
   Lydia L. Shook, Parisa Nicole Fallah, Jason N. Silberman, Andrea G. Edlow · 2021 · Frontiers in Cellular and Infection Microbiology
5. Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex
   Chapin S. Korosec, Suzan Farhang‐Sardroodi, David W. Dick, Sameneh Gholami, Mohammad Sajjad Ghaemi, Iain R. Moyles, Morgan Craig, Hsu Kiang Ooi, Jane Marie Heffernan · 2022 · Scientific Reports
6. Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines
   Violette Mouro, Alain Fischer · 2022 · Mucosal Immunology
7. Gut microbiota-derived metabolites confer protection against SARS-CoV-2 infection
   Julia A. Brown, Katherine Z. Sanidad, Serena Lucotti, Carolin M. Lieber, Robert M. Cox, Aparna Ananthanarayanan, Srijani Basu, Justin B. Chen, Mengrou Shan, Mohammed Amir et al. · 2022 · Gut Microbes
8. Neutralizing Antibodies Titers and Side Effects in Response to BNT162b2 Vaccine in Healthcare Workers with and without Prior SARS-CoV-2 Infection
   José Javier Morales‐Núñez, José Francisco Muñóz-Valle, Carlos Meza-López, Lin‐Fa Wang, Andrea Carolina Machado-Sulbarán, Paola Carolina Torres-Hernández, Martín Bedolla‐Barajas, Brenda De la O-Gómez, Paulina Balcázar-Félix, Jorge Hernández‐Bello · 2021 · Vaccines
9. Modeling how antibody responses may determine the efficacy of COVID-19 vaccines
   Pranesh Padmanabhan, Rajat Desikan, Narendra M. Dixit · 2022 · Nature Computational Science
10. Distinct immune cell dynamics correlate with the immunogenicity and reactogenicity of SARS-CoV-2 mRNA vaccine
    Tomohiro Takano, Miwa Morikawa, Yu Adachi, Kiyomi Kabasawa, Nicolas Sax, Saya Moriyama, Lin Sun, Masanori Isogawa, Ayae Nishiyama, Taishi Onodera et al. · 2022 · Cell Reports Medicine
11. Pre-existing immunity modulates responses to mRNA boosters
    Tanushree Dangi, Sarah Sanchez, Min Han Lew, Bakare Awakoaiye, Lavanya Visvabharathy, Justin M. Richner, Igor Jerome Koralnik, Pablo Penaloza‐MacMaster · 2023 · Cell Reports
12. Updated Results of the COVID-19 in MS Global Data Sharing Initiative
    Steve Simpson, Ashkan Pirmani, Tomáš Kalinčík, Edward De Brouwer, Lotte Geys, Tina Parciak, Anne E. Helme, Nick Rijke, Jan A. Hillert, Yves Moreau et al. · 2022 · Neurology Neuroimmunology & Neuroinflammation
13. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people
    Tara M. Narowski, Kristin Raphel, Lily E. Adams, Jenny Huang, Nadja A. Vielot, Ramesh Jadi, Aravinda M. de Silva, Ralph Steven Baric, John Lafleur, Lakshmanane Premkumar · 2022 · Cell Reports
14. Monitoring Serum Spike Protein with Disposable Photonic Biosensors Following SARS-CoV-2 Vaccination
    John S. Cognetti, Benjamin L. Miller · 2021 · Sensors
15. Cellular and Humoral Functional Responses After BNT162b2 SARS-CoV-2 mRNA Vaccination Differ Between Naïve and COVID-19-Recovered Individuals
    Roberto Lozano‐Rodríguez, Jaime Valentín‐Quiroga, José Avendaño Ortiz, Alejandro Martín‐Quirós, Alejandro Pascual‐Iglesias, Verónica Terrón‐Arcos, Karla Marina Montalbán-Hernández, José Carlos Casalvilla‐Dueñas, Marta Bergón-Gutiérrez, José Alcamı́ et al. · 2021 · Cell Reports
16. Analysis of mRNA vaccination-elicited RBD-specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 Omicron variant
    Sokal, Aurélien, Broketa, Matteo, Barba-Spaeth, Giovanna, Meola, Annalisa, Fernández, Ignacio, Fourati, Slim, Azzaoui, Imane, de La Selle, Andrea, Vandenberghe, Alexis, Roeser, Anais et al. · 2022 · Immunity
17. Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters
    Rachel M. Burckhardt, John J. Dennehy, Leo L. M. Poon, Linda J. Saif, Lynn W. Enquist · 2021 · Journal of Virology
18. Smart Mushroom-Inspired Imprintable and Lightly Detachable (MILD) Microneedle Patterns for Effective COVID-19 Vaccination and Decentralized Information Storage
    Qilin Li, Rengui Xu, Huiling Fan, Jiarong Xu, Yunruo Xu, Peng Cao, Yan Zhang, Tao Liang, Yang Zhang, Wei Chen et al. · 2022 · ACS Nano
19. SARS-CoV-2 XBB.1.5 mRNA booster vaccination elicits limited mucosal immunity
    Ninaad Lasrado, Marjorie Rowe, Katherine McMahan, Nicole P. Hachmann, Jessica J Miller, Catherine Jacob-Dolan, Jinyan Liu, Brookelynne Verrette, Kristin A. Gotthardt, Darren Ty et al. · 2024 · Science Translational Medicine
20. Vaccination versus infection with SARS‐CoV‐2: Establishment of a high avidity IgG response versus incomplete avidity maturation
    Friedhelm Struck, Patrick A. Schreiner, Eva Staschik, Karin Wochinz‐Richter, Sarah Schulz, Erwin Soutschek, Manfred Motz, Georg Bauer · 2021 · Journal of Medical Virology
21. Pre-existing immunity and vaccine history determine hemagglutinin-specific CD4 T cell and IgG response following seasonal influenza vaccination
    Katharina Wild, Maike Smits, Saskia Killmer, Shirin Strohmeier, Christoph Neumann‐Haefelin, Bertram Bengsch, Florian Krammer, Martin Schwemmle, Maike Hofmann, Robert Thimme et al. · 2021 · Nature Communications
22. Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients
    Nicholas Kim Huat Khoo, Joey Ming Er Lim, Upkar S. Gill, Ruklanthi de Alwis, Nicole Tan, Justin Zhen Nan Toh, Jane E. Abbott, Carla Usai, Eng Eong Ooi, Jenny Guek Hong Low et al. · 2022 · Med
23. Airway antibodies emerge according to COVID-19 severity and wane rapidly but reappear after SARS-CoV-2 vaccination
    Alberto Cagigi, Meng Yu, Björn Österberg, Julia Svensson, Sara Falck‐Jones, Sindhu Vangeti, Eric Åhlberg, Lida Azizmohammadi, Anna Warnqvist, Ryan Falck‐Jones et al. · 2021 · JCI Insight
24. mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron
    Hye‐Kyung Lee, Ludwig Knabl, Juan I. Moliva, Ludwig Knabl, Anne P. Werner, Seyhan Boyoglu-Barnum, Sebastian Kapferer, Birgit Pateter, Mary Walter, Nancy J. Sullivan et al. · 2022 · Cell Reports
25. The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection
    Esther Moga, Elionor Lynton‐Pons, Peré Domingo · 2022 · Frontiers in Immunology
26. Variations within the Glycan Shield of SARS-CoV-2 Impact Viral Spike Dynamics
    Maddy L. Newby, Carl A. Fogarty, Joel D. Allen, John Butler, Elisa Fadda, Max Crispin · 2022 · Journal of Molecular Biology
27. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity
    Kathryn A. Bowman, Daniel Stein, Sally A. Shin, Kathie G. Ferbas, Nicole H. Tobin, Colin J. Mann, Stephanie Fischinger, Erica Ollmann Saphire, Douglas A. Lauffenburger, Anne W. Rimoin et al. · 2022 · mBio
28. Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines
    Manish K. Dhawan, Ali Ahmed Rabaan, Mahmoud M. Fawarah, Souad A. Almuthree, Roua Abdullah Alsubki, Amal H. Alfaraj, Mutaib M. Mashraqi, Saleh Alshamrani, Wesam A. Abduljabbar, Ameen S. S. Alwashmi et al. · 2023 · Vaccines
29. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2
    Sebastian Havervall, Ulrika Wimmercranz Marking, Nina Greilert‐Norin, Henry Ng, Max Gordon, Ann‐Christin Salomonsson, Cecilia Hellström, Elisa Pin, Kim G. Blom, Sara M. Mangsbo et al. · 2021 · EBioMedicine
30. Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern
    Ankita Saha, Sounak Ghosh Roy, Richa Dwivedi, Prajna Tripathi, Kamal Kumar, Shashank Manohar Nambiar, Rajiv Pathak · 2025 · Vaccines
31. COVID ‐19 and plasma cells: Is there long‐lived protection?*
    Doan C. Nguyen, Pedro A. Lamothe, Matthew Charles Woodruff, Ankur Singh Saini, Caterina Elisa Faliti, Igñacio Sanz, Frances Eun-Hyung Lee · 2022 · Immunological Reviews
32. SARS-CoV-2—The Role of Natural Immunity: A Narrative Review
    Sara Diani, Erika A. Leonardi, Attilio Cavezzi, Simona Ferrari, Oriana Iacono, Alice Limoli, Zoe Bouslenko, Daniele Natalini, Stefania Conti, Mauro Mantovani et al. · 2022 · Journal of Clinical Medicine
33. Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment
    A. Grinshpun, Y. Rottenberg, I. Ben-Dov, E. Djian, D. G. Wolf, L. Kadouri · 2021 · ESMO Open
34. AS03 adjuvant enhances the magnitude, persistence, and clonal breadth of memory B cell responses to a plant-based COVID-19 vaccine in humans
    Lilit Grigoryan, Yupeng Feng, Lorenza Bellusci, Lilin Lai, Bushra Wali, Madison Leigh Ellis, Meng Yuan, Prabhu S. Arunachalam, Mengyun Hu, Sangeeta Kowli et al. · 2024 · Science Immunology
35. Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination
    William N. Voss, Michael L. Mallory, Patrick O. Byrne, Jeffrey Marchioni, Sean A. Knudson, John M. Powers, Sarah R. Leist, Bernadeta Dadonaite, Douglas R. Townsend, Jessica Kain et al. · 2024 · Cell Reports Medicine
36. Early human B cell signatures of the primary antibody response to mRNA vaccination
    Lela Kardava, Nicholas Rachmaninoff, William W. Lau, Clarisa M. Buckner, Krittin Trihemasava, Felipe Lopes de Assis, Wei Wang, Xiaozhen Zhang, Yimeng Wang, Chi-I Chiang et al. · 2022 · Proceedings of the National Academy of Sciences
37. Secretory IgA and T cells targeting SARS-CoV-2 spike protein are transferred to the breastmilk upon mRNA vaccination
    Juliana Gonçalves, A. Margarida Juliano, Nádia Charepe, Marta Alenquer, Diogo Athayde, Filipe Ferreira, Margarida Archer, Maria João Amorim, Fátima Serrano, Helena Soares · 2021 · Cell Reports Medicine
38. Correlates of protection against symptomatic SARS-CoV-2 in vaccinated children
    Youjia Zhong, Alicia Yi Hui Kang, Carina Jing Xuan Tay, Hui’ En Li, Nurul Elyana, Chee Wah Tan, Wee Chee Yap, Joey Ming Er Lim, Nina Le Bert, Kuan Rong Chan et al. · 2024 · Nature Medicine
39. Influence of age, gender, previous SARS-CoV-2 infection, and pre-existing diseases in antibody response after COVID-19 vaccination: A review
    Maria da Conceição Rodrigues Fernandes, Germana Silva Vasconcelos, Amanda Campelo Lima de Melo, Tamires Cardoso Matsui, Ludmilla Freire Caetano, Fernanda Montenegro de Carvalho Araújo, Marcela Helena Gambim Fonseca · 2023 · Molecular Immunology
40. HLA‐DR polymorphism in SARS‐CoV‐2 infection and susceptibility to symptomatic COVID‐19
    Stuart Astbury, Catherine J. Reynolds, David K. Butler, Diana Mūnoz Sandoval, Kai‐Min Lin, Franziska P. Pieper, Ashley David Otter, Afroditi Kouraki, Lola Cusin, Jessica Nightingale et al. · 2022 · Immunology
41. Impact of Distinct Therapies on Antibody Response to SARS‐CoV ‐2 Vaccine in Systemic Lupus Erythematosus
    Emily Figueiredo Neves Yuki, Eduardo Ferreira Borba, Sandra Gofinet Pasoto, Luciana Parente Costa Seguro, Michelle Remião Ugolini Lopes, Carla Gonçalves Schahin Saad, Ana Cristina de Medeiros Ribeiro, Clóvis A. Silva, DANIELI CASTRO OLIVEIRA DE ANDRADE, Léonard de Vinci Kanda Kupa et al. · 2021 · Arthritis Care & Research
42. Immune responses to Sinopharm/ BBIBP‐CorV in individuals in Sri Lanka
    Chandima Jeewandara, Inoka Sepali Aberathna, Pradeep Darshana Pushpakumara, Achala Kamaladasa, Dinuka Guruge, Ayesha Wijesinghe, Banuri Gunasekera, Shyrar Tanussiya, Heshan Kuruppu, Thushali Ranasinghe et al. · 2022 · Immunology
43. Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination
    Cho, Alice, Muecksch, Frauke, Schaefer-Babajew, Dennis, Wang, Zijun, Finkin, Shlomo, Gaebler, Christian, Ramos, Victor, Cipolla, Melissa, Mendoza, Pilar, Agudelo, Marianna et al. · 2021
44. SARS-CoV-2 infection and vaccination trigger long-lived B and CD4+ T lymphocytes with implications for booster strategies
    Alessio Mazzoni, Anna Vanni, Michele Spinicci, Giulia Lamacchia, Seble Tekle Kiros, Arianna Rocca, Manuela Capone, Nicoletta Di Lauria, Lorenzo Salvati, Alberto Carnasciali et al. · 2022 · Journal of Clinical Investigation
45. The past, current and future epidemiological dynamic of SARS-CoV-2
    François Balloux, Cedric C.S. Tan, Leo Swadling, Damien Richard, Charlotte Jenner, Mala K. Maini, Lucy van Dorp · 2022 · Oxford Open Immunology
46. Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination
    Grace E. Mantus, Lindsay E. Nyhoff, Venkata Viswanadh Edara, Veronika I. Zarnitsyna, Caroline Rose Ciric, Maria W. Flowers, Carson Norwood, Madison Leigh Ellis, Laila Hussaini, Kelly E. Manning et al. · 2022 · Cell Reports Medicine
47. Neutralization of Delta variant with sera of Covishield™ vaccinees and COVID-19-recovered vaccinated individuals
    Gajanan N. Sapkal, Pragya Dhruv Yadav, Rima Rakeshkumar Sahay, Gururaj Rao Deshpande, Nivedita Gupta, Dimpal A. Nyayanit, Deepak Y. Patil, Anita M. Shete, Sanjay Kumar, Priya Abraham et al. · 2021 · Journal of Travel Medicine
48. Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses
    Patricia Almendro-Vázquez, Marta Chivite‐Lacaba, Alberto Utrero‐Rico, Cecilia González‐Cuadrado, Rocío Laguna‐Goya, Miguel Moreno-Batanero, Laura Sánchez-Paz, Joanna Luczkowiak, Nuria Labiod, María Dolores Folgueira et al. · 2022 · Frontiers in Immunology
49. Subcutaneous BCG vaccination protects against streptococcal pneumonia via regulating innate immune responses in the lung
    Alisha Kang, Gluke Ye, Ramandeep Singh, Sam Afkhami, Jegarubee Bavananthasivam, Xiangqian Luo, Maryam Vaseghi‐Shanjani, Fatemah Aleithan, Anna Zganiacz, Mangalakumari Jeyanathan et al. · 2023 · EMBO Molecular Medicine
50. Maintenance and functional regulation of immune memory to COVID-19 vaccines in tissues
    Julia Davis‐Porada, Alex B. George, Nora Lam, Daniel P. Caron, Joshua I. Gray, Jenny Huang, Jennifer Hwu, Steven B. Wells, Rei Matsumoto, Masaru Kubota et al. · 2024 · Immunity
51. SARS-CoV-2 antibody and T cell responses one year after COVID-19 and the booster effect of vaccination: A prospective cohort study
    Willem Ashwin Mak, Johannes G.M. Koeleman, Marijke van der Vliet, Frans Keuren, David S. Y. Ong · 2021 · Journal of Infection
52. Decreased memory B cell frequencies in COVID‐19 delta variant vaccine breakthrough infection
    Matthew Zirui Tay, Angéline Rouers, Siew‐Wai Fong, Yun Shan Goh, Yi‐Hao Chan, Zi Wei Chang, Weili Xu, Chee Wah Tan, Wan Ni Chia, Anthony Torres‐Ruesta et al. · 2022 · EMBO Molecular Medicine
53. Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants
    Severino Jefferson Ribeiro da Silva, Suelen Cristina de Lima, Ronaldo Celerino da Silva, Alain Kohl, Lindomar Pena · 2022 · Frontiers in Medicine
54. SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared with SARS-CoV-2 mRNA vaccinations
    Elizabeth M. Anderson, Shuk Hang Li, Moses Awofolaju, Theresa Eilola, Eileen C. Goodwin, Marcus J. Bolton, Sigrid Gouma, Tomaz B. Manzoni, Philip D. Hicks, Rishi R. Goel et al. · 2022 · Cell Reports
55. B cells: The many facets of B cells in allergic diseases
    Pattraporn Satitsuksanoa, Sayuri Iwasaki, Jolien Boersma, Manal Bel Imam, Stephan R. Schneider, Iris Chang, Willem van de Veen, Mübeccel Akdiş · 2023 · Journal of Allergy and Clinical Immunology
56. Specific Anti-SARS-CoV-2 Humoral and Cellular Immune Responses After Booster Dose of BNT162b2 Pfizer-BioNTech mRNA-Based Vaccine: Integrated Study of Adaptive Immune System Components
    Rosalia Busà, Maria Concetta Sorrentino, Giovanna Russelli, Giandomenico Amico, Vitale Miceli, Monica Miele, Mariangela Di Bella, Francesca Timoneri, Alessia Gallo, Giovanni Zito et al. · 2022 · Frontiers in Immunology
57. Immune correlates of protection for SARS-CoV-2, Ebola and Nipah virus infection
    Beatriz Escudero-Pérez, Philip Lawrence, Javier Castillo‐Olivares · 2023 · Frontiers in Immunology
58. Immunogenicity and reactogenicity of intradermal mRNA-1273 SARS-CoV-2 vaccination: a non-inferiority, randomized-controlled trial
    Margaretha Prins, Geert V.T. Roozen, Cilia R. Pothast, Wesley Huisman, Rob S. van Binnendijk, Gerco den Hartog, Vincent P. Kuiper, Corine Prins, Jacqueline J. Janse, Olivia A. C. Lamers et al. · 2024 · npj Vaccines
59. Trivalent nucleoside-modified mRNA vaccine yields durable memory B cell protection against genital herpes in preclinical models
    Sita Awasthi, James J. Knox, Angela Desmond, Mohamad-Gabriel Alameh, Brian T. Gaudette, John M. Lubinski, Alexis Naughton, Lauren M. Hook, Kevin P. Egan, Ying K. Tam et al. · 2021 · Journal of Clinical Investigation
60. Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges
    João Faro Viana, Marie‐Louise Bergman, Lígia Antunes Gonçalves, Nádia Duarte, Teresa Penha Coutinho, Patrícia Borges, Christian Diwo, Rute Castro, Paula Matoso, Vanessa Malheiro et al. · 2022 · Nature Communications
61. Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine
    Alexandra Tauzin, Alexandre Nicolas, Shilei Ding, Mehdi Benlarbi, Halima Medjahed, Debashree Chatterjee, Katrina Dionne, Shang Yu Gong, Gabrielle Gendron‐Lepage, Yuxia Bo et al. · 2023 · Cell Reports
62. Molecular Mimicry of the Viral Spike in the SARS-CoV-2 Vaccine Possibly Triggers Transient Dysregulation of ACE2, Leading to Vascular and Coagulation Dysfunction Similar to SARS-CoV-2 Infection
    Christian Albert Devaux, Laurence Camoin‐Jau · 2023 · Viruses
63. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity
    Sonia Tejedor Vaquero, Leire de Campos‐Mata, José María Ramada, Pilar Díaz, Juan Navarro‐Barriuso, Clara Ribas‐Llauradó, Natalia Rodrigo Melero, Carlo Carolis, Andrea Cerutti, Ramón Gimeno et al. · 2021 · Frontiers in Immunology
64. High–temporal resolution profiling reveals distinct immune trajectories following the first and second doses of COVID-19 mRNA vaccines
    Darawan Rinchai, Sara Deola, Gabriele M. Zoppoli, Basirudeen Syed Ahamed Kabeer, Sara Taleb, Igor Pavlovski, Selma Maacha, Giusy Gentilcore, Mohammed Toufiq, Lisa Sara Mathew et al. · 2022 · Science Advances
65. Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2
    Jorge Hernández‐Bello, José Javier Morales‐Núñez, Andrea Carolina Machado-Sulbarán, Saúl Alberto Díaz-Pérez, Paola Carolina Torres-Hernández, Paulina Balcázar-Félix, Jesús Alberto Gutiérrez-Brito, José Álvaro Lomelí-Nieto, José Francisco Muñóz-Valle · 2021 · Vaccines
66. SARS-CoV-2 spike-specific memory B cells express higher levels of T-bet and FcRL5 after non-severe COVID-19 as compared to severe disease
    Raphael A. Reyes, Kathleen Clarke, S. Jake Gonzales, Angelene M. Cantwell, Rolando Garza, Gabriel Catano, Robin E. Tragus, Thomas F. Patterson, Sebastiaan M. Bol, Evelien M. Bunnik · 2021 · PLoS ONE
67. SARS -CoV-2 T-cell immunity to variants of concern following vaccination
    Kathleen Gallagher, Mark B. Leick, Rebecca C. Larson, Trisha R. Berger, Katelin Katsis, Jennifer Y. Yam, Gabrielle Brini, Korneel Grauwet, MGH COVID-19 Collection & Processing Team, Marcela Valderrama Maus · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
68. Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening
    Azucena Ramos, Catherine E. Koch, Yunpeng Liu-Lupo, Riley D. Hellinger, Taeyoon Kyung, Keene L. Abbott, Julia Fröse, Daniel R. Goulet, Khloe S. Gordon, Keith P. Eidell et al. · 2023 · Nature Communications
69. Antibody response after one and two jabs of the BNT162b2 vaccine in nursing home residents: The CONsort‐19 study
    Hubert Blain, Édouard Tuaillon, Lucie Gamon, Amandine Pisoni, Stéphanie Miot, Yves Rolland, Marie‐Christine Picot, Jean J. Bousquet · 2021 · Allergy
70. Challenges and Scientific Prospects of the Newest Generation of mRNA-Based Vaccines against SARS-CoV-2
    Daniela Cornelia Călina, Antonio F. Hernández, Thomas Härtung, Alexey M. Egorov, Boris Nikolaevich Izotov, Τaxiarchis Κonstantinos Νikolouzakis, Aristidis Michael Tsatsakis, Panayiotis G. Vlachoyiannopoulos, Anca Oana Docea · 2021 · Life
71. Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial
    Daniel Mrak, Daniela Sieghart, Elisabeth Simader, Selma Tobudic, Helga Radner, Péter Mandl, Lisa Göschl, Maximilian Koblischke, Nikolaus Hommer, Angelika Wagner et al. · 2022 · Nature Communications
72. SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans
    David Forgacs, Hyesun Jang, Rodrigo B. Abreu, Hannah B. Hanley, Jasper L. Gattiker, Alexandria M. Jefferson, Ted M. Ross · 2021 · Frontiers in Immunology
73. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection
    Meghan E. Garrett, Jared G. Galloway, Caitlin Wolf, Jennifer K. Logue, Nicholas Franko, Helen Y. Chu, Frederick A. Matsen IV, Julie Overbaugh · 2022 · eLife
74. Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals
    Thomas Lechmere, Luke B. Snell, Carl Graham, Jeffrey Seow, Zayed A. Shalim, Themoula Charalampous, Adela Alcolea-Medina, Rahul Batra, Gaia Nebbia, Jonathan D. Edgeworth et al. · 2022 · mBio
75. Navigating the Post-COVID-19 Immunological Era: Understanding Long COVID-19 and Immune Response
    Aditi Mohan, Venkatesh Anand Iyer, Dharmender Kumar, Lalit Batra, Praveen Dahiya · 2023 · Life
76. Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals
    Lederer, Katlyn, Parvathaneni, Kalpana, Painter, Mark M., Bettini, Emily, Agarwal, Divyansh, Lundgreen, Kendall A., Weirick, Madison, Goel, Rishi R., Xu, Xiaoming, Drapeau, Elizabeth M. et al. · 2021
77. Neutralizing Anti-SARS-CoV-2 Antibody Titer and Reported Adverse Effects, in a Sample of Italian Nursing Home Personnel after Two Doses of the BNT162b2 Vaccine Administered Four Weeks Apart
    Alberto Modenese, Stefania Paduano, Annalisa Bargellini, Rossana Bellucci, Simona Marchetti, Fulvio Bruno, Pietro Grazioli, Roberto Vivoli, Fabriziomaria Gobba · 2021 · Vaccines
78. The kinetics of IgG subclasses and contributions to neutralizing activity against SARS‐CoV‐2 wild‐type strain and variants in healthy adults immunized with inactivated vaccine
    Weixin Chen, Lichi Zhang, Juan Li, Shuang Bai, Yali Wang, Bing Zhang, Qun Zheng, Meng Chen, Wei Zhao, Jiang Wu · 2022 · Immunology
79. Advancing personalized medicine in brain cancer: exploring the role of mRNA vaccines
    Feng Lin, Emma Z. Lin, Misa Anekoji, Thomas E. Ichim, Joyce K. Hu, Francesco Maria Marincola, Lawrence D. Jones, Santosh Kesari, Shashaanka Ashili · 2023 · Journal of Translational Medicine
80. Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study
    Nádia Emi Aikawa, Léonard de Vinci Kanda Kupa, Sandra Gofinet Pasoto, Ana Cristina de Medeiros Ribeiro, Emily Figueiredo Neves Yuki, Carla Gonçalves Schahin Saad, Tatiana do Nascimento Pedrosa, Ricardo Fuller, Samuel Katsuyuki Shinjo, Percival Degrava Sampaio-Barros et al. · 2021 · The Lancet Rheumatology
81. Neutralizing antibody: a savior in the Covid-19 disease
    Sneh Lata Gupta, Rishi Kumar Jaiswal · 2022 · Molecular Biology Reports
82. Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development
    Günl, Franziska, Mecate-Zambrano, Angeles, Rehländer, Selina, Hinse, Saskia, Ludwig, Stephan, Brunotte, Linda · 2021 · Vaccines
83. What Happens to the Immune System after Vaccination or Recovery from COVID-19?
    Bruna Tiaki Tiyo, Gabriela J. H. Schmitz, Marina Mazzilli Ortega, Laís T. da Silva, Alexandre de Almeida, Telma Miyuki Oshiro, Alberto José da Silva Duarte · 2021 · Life
84. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern
    Marit J. van Gils, Hugo D.G. van Willigen, Elke Wynberg, Alvin X. Han, Karlijn van der Straten, Judith A. Burger, Meliawati Poniman, Melissa Oomen, Khadija Tejjani, Joey H. Bouhuijs et al. · 2021 · Cell Reports Medicine
85. Sex, Age, and Ethnic Background Shape Adaptive Immune Responses Induced by the SARS-CoV-2 mRNA Vaccine
    Jie Bai, Asako Chiba, Goh Murayama, Taiga Kuga, Naoto Tamura, Sachiko Miyake · 2022 · Frontiers in Immunology
86. COVID-19 breakthrough infections and humoral immune response among BNT162b2 vaccinated healthcare workers in Malaysia
    Su Lan Yang, Adiratna Mat Ripen, Chin Tho Leong, Jen Ven Lee, Chia How Yen, Avinash Kumar Chand, Karina Koh, Nur Aisyah Binti Abdul Rahim, Varaalakshmy Gokilavanan, Nik Nur Eliza Mohamed et al. · 2022 · Emerging Microbes & Infections
87. Immunogenicity and efficacy of Ad26. COV2 .S: An adenoviral vector–based COVID ‐19 vaccine
    Mathieu Le Gars, Jenny Hendriks, JERALD C. SADOFF, Martin Ryser, Frank Struyf, Macaya Douoguih, Hanneke Schuitemaker · 2022 · Immunological Reviews
88. Persistent Maintenance of Intermediate Memory B Cells Following SARS-CoV-2 Infection and Vaccination Recall Response
    Jernej Pušnik, Julia König, Karola Mai, Enrico Richter, Jasmin Zorn, Hannah Proksch, Bianca Schulte, Galit Alter, Hendrik Streeck · 2022 · Journal of Virology
89. A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses
    Alexandra Tauzin, Shang Yu Gong, Debashree Chatterjee, Shilei Ding, Mark M. Painter, Rishi R. Goel, Guillaume Beaudoin-Bussières, Lorie Marchitto, Marianne Boutin, Annemarie Laumaea et al. · 2022 · Cell Reports
90. An optimized flow cytometry protocol for simultaneous detection of T cell activation induced markers and intracellular cytokines: Application to SARS-CoV-2 immune individuals
    Tiziana Altosole, Gianluca Rotta, Chiara Uras, Scott J. Bornheimer, Daniela Fenoglio · 2023 · Journal of Immunological Methods
91. Is one vaccine dose enough if you’ve had COVID? What the science says
    Elie Dolgin · 2021 · Nature
92. Three immunizations with Novavax’s protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2
    Klara Lenart, Rodrigo Arcoverde Cerveira, Fredrika Hellgren, Sebastian Ols, Daniel J. Sheward, Changil Kim, Alberto Cagigi, Matthew Gagné, Brandon J. Davis, Daritza Germosen et al. · 2024 · npj Vaccines
93. SARS-CoV-2 booster vaccine dose significantly extends humoral immune response half-life beyond the primary series
    Chapin S. Korosec, David W. Dick, Iain R. Moyles, James Watmough · 2024 · Scientific Reports
94. Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapies
    Roberto Alfonso, Jerry Lin, Vanessa Kirschner, Joyce Lei, Grant Feuer, Michaela L. Malin, Jiayuan Liu, Morgan Roche, Saud Ahmed Sadiq · 2022 · Frontiers in Immunology
95. Engineered immunogens to elicit antibodies against conserved coronavirus epitopes
    2023
96. Clinical Utility of SARS-CoV-2 Serological Testing and Defining a Correlate of Protection
    Kimia Sobhani, Susan C. Cheng, Raquel A. Binder, Nicholas John Mantis, James M. Crawford, Nkemakonam C. Okoye, Jonathan G. Braun, Sandy Y. Joung, Minhao Wang, Gerard Lozanski et al. · 2023 · Vaccines
97. Strong antibody response after a first dose of a SARS-CoV-2 mRNA-based vaccine in kidney transplant recipients with a previous history of COVID-19
    Iliès Benotmane, Gabriela Gautier-Vargas, Floriane Gallais, Pierre Gantner, Noëlle Cognard, Jérôme Olagne, Aurélie Velay, Françoise Heibel, Laura Braun-Parvez, Jonas Martzloff et al. · 2021 · American Journal of Transplantation
98. Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant
    Ruiqi Zhang, Ka-Wa Khong, Ka‐Yi Leung, Danlei Liu, Yujing Fan, Lu Lu, Pui-Chun Chan, Lin‐Lei Chen, Kelvin Kai‐Wang To, Honglin Chen et al. · 2021 · Vaccines
99. AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2
    Marah G. Chibwana, Thandeka Moyo-Gwete, Gaurav Kwatra, Jonathan J. Mandolo, Tandile Hermanaus, Thopisang P. Motlou, Nonkululeko B. Mzindle, Frances Ayres, Mphatso Chaponda, Godwin Tembo et al. · 2022 · BMC Medicine
100. Impact of SARS‐CoV‐2 infection on vaccine‐induced immune responses over time
     Sebastian Havervall, Ulrika Wimmercranz Marking, Nina Greilert‐Norin, Max Gordon, Henry Ng, Wanda Christ, Mia Phillipson, Peter Nilsson, Sophia Hober, Kim G. Blom et al. · 2022 · Clinical & Translational Immunology